Background Advanced triple-negative breast cancer (TNBC) is prone to brain metastasis (BrM). The precise molecular mechanism responsible for this phenomenon has not yet been completely established, so it is vital to comprehend the molecular mechanism behind it. Methods The protein chip analysis was conducted to identify any abnormal UBE2T protein expression in TNBC, especially BrM.… Continue reading UBE2T/CDC42/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagy
Tag: Breast Cancer
Community‐engaged adaptation of ACCESS: A navigator‐led early palliative care intervention for Black and Latina women with advanced breast cancer
Abstract Introduction Disparities in early palliative care (PC) access for Black and Latina women with advanced breast cancer (ABC) persist. This study elicited qualitative feedback from patients with ABC and health professionals to adapt a community navigator-led early PC program called ACCESS to improve PC access and supportive care outcomes for Black and Latina women… Continue reading Community‐engaged adaptation of ACCESS: A navigator‐led early palliative care intervention for Black and Latina women with advanced breast cancer
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
Cholangiocarcinoma (CCA) is a diverse group of epithelial malignant tumors arising from the biliary tract, characterized by high molecular heterogeneity. It is classified into intrahepatic (iCCA) and extrahepatic CCA (eCCA) based on the location of the primary tumor. CCA accounts for approximately 15% of all primary liver cancers, with iCCA comprising 10–20% of all CCAs.… Continue reading Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
[ASAP] A Stereoselective Decarboxylative Aromatase/Cyclase Directs the Biosynthesis of an Axially Chiral Biphenyl Framework in Fasamycin
[ASAP] Reactive Oxygen Species Inducing Triazolylpyridine-Based Ru(II)/Ir(III) Complexes for Therapeutically Enhanced Triple-Negative Breast Cancer Treatment
Whole genome sequencing powered ctDNA sequencing for breast cancer detection
Circulating tumour DNA (ctDNA) based detection of Molecular Residual Disease (MRD) presents a strategy to identify patients at high risk of relapse. Here we profile early breast cancer patients with an ultrasensitive, whole genome sequencing-based, tumour-informed ctDNA platform.
Inhibitor drugs to treat aggressive breast cancer identified
A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.
[ASAP] Correction to “Discovery, Synthesis, and Evaluation of Novel Dual Inhibitors of a Vascular Endothelial Growth Factor Receptor and Poly(ADP-Ribose) Polymerase for BRCA Wild-Type Breast Cancer Therapy”
[ASAP] Platinum(IV) Complexes Trigger Death Receptors and Natural Killer Cells to Suppress Breast Cancer
[ASAP] Application of a CYP1B1-Targeted NIR Probe for Breast Cancer Diagnosis, Surgical Navigation, and CYP1B1-Associated Chemotherapy Resistance Monitoring
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.4c01223